Compounds > fecosterol
Page last updated: 2024-12-08

fecosterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID440371
CHEBI ID17038
SCHEMBL ID20641220
MeSH IDM0117607

Synonyms (26)

Synonym
LMST01030095
24-methylene-cholest-8-en-3beta-ol
24-methylidene-5alpha-cholest-8-en-3beta-ol
CHEBI:17038
24-methylene-5alpha-cholest-8-en-3beta-ol
fecosterol ,
516-86-9
C04525
(3s,5s,10s,13r,14r,17r)-10,13-dimethyl-17-[(2r)-6-methyl-5-methylideneheptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
48a2ty6k38 ,
ergosta-8,24(28)-dien-3-ol, (3beta,5alpha)-
unii-48a2ty6k38
delta-8(24),28-ergostadienol
8(9), (5-alpha)-cholesten-24-methylene-3-beta-ol
ergosta-8,24(28)-dien-3-ol, (3.beta.,5.alpha.)-
DTXSID90199553
AKOS027326592
(3s,5s,10s,13r,14r,17r)-17-[(1r)-1,5-dimethyl-4-methylene-hexyl]-10,13-dimethyl-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
Q15410975
SCHEMBL20641220
(3.beta.,5.alpha.)-ergosta-8,24(28)-dien-3-ol
(3s,5s,10s,13r,14r,17r)-17-((1r)-1,5-dimethyl-4-methylene-hexyl)-10,13-dimethyl-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1h-cyclopenta(a)phenanthren-3-ol
.delta.8,24(28)-ergostadienol
5.alpha.-ergosta-8,24(28)-dien-3.beta.-ol
HY-141457
CS-0169549
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Cholesterol biosynthesis and metabolism CE(14:0)2250
Cholesterol biosynthesis and metabolism CE(10:0)2250
Cholesterol Biosynthesis and Metabolism CE(12:0)2250
Cholesterol Biosynthesis and Metabolism CE(16:0)2250
Cholesterol biosynthesis and metabolism CE(18:0)2250
Cholesterol Biosynthesis and Metabolism2248
Ergosterol biosynthesis332
superpathway of ergosterol biosynthesis I2156
ergosterol biosynthesis I514
superpathway of ergosterol biosynthesis2256
ergosterol biosynthesis514
superpathway of sterol biosynthesis050

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.17 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		1.9710dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride
trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride: An anti-cholesteremic agent that inhibits delta 7-reductase, delta 14 reductase, and sterol biosynthesis.		1.9610
potassium phosphate
potassium phosphate: used in dental materials and to treat hypophosphatemia; RN given refers to cpd with unspecified MF. tripotassium phosphate : An inorganic potassium salt that is the tripotassium salt of phosphoric acid.		2.110inorganic phosphate salt;
inorganic potassium salt
zymosterol
[no description available]		1.96103beta-sterol;
cholestanoid		human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ergosterol
[no description available]		2.92403beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials